跳至主要内容
临床试验/NCT04679285
NCT04679285已完成不适用

Pilot Study to Assess Minimal Residual Disease on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

University Hospital, Lille1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2021年4月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
9
试验地点
1
主要终点
Percentage of patients without detectable MRD in ovarian tissue

研究概览

简要总结

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation.

This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
2 Years 至 40 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Patient diagnosed with AML
  • At least one molecular marker identified at AML diagnosis
  • Patients who undergo ovarian tissue cryopreservation for fertility preservation in complete remission, before hematopoietic stem cell transplantation.

排除标准

  • Other diagnostic
  • No marker available at AML diagnosis
  • No bone marrow/ovarian fragment available at the time of complete remission

结局指标

主要结局

Percentage of patients without detectable MRD in ovarian tissue

时间窗: Up to 6 months

次要结局

  • Percentage of patients with MRD detected in ovarian tissue and bone marrow.(Up to 1 month)

研究者

发起方
University Hospital, Lille
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验